Biomarkers for liver fibrotic injury
The present invention provides a method for detecting liver fibrotic injury, including fibrosis and/or cirrhosis, by assaying biological samples for differential expression of at least one gene encoding a protein chosen from SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof, wherein differential expression of at least one gene suggests the presence of liver fibrosis or cirrhosis. The invention also provides a kit containing nucleic acid probes or antibodies for detecting liver fibrosis and/or cirrhosis by assaying the differential expression of proteins encoded by SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof.
1. A method of detecting liver fibrosis and/or cirrhosis comprising:
obtaining a first biological sample from a first subject without liver fibrosis and/or cirrhosis, wherein the first subject is a normal subject;
obtaining a second biological sample from a second subject known or suspected of having liver fibrosis and/or cirrhosis; and
determining an amount of at least one protein chosen from SEQ ID NO: 7 and SEQ ID NO: 68 in said first and second biological samples;
wherein a difference of 1.5 fold or more between the amount of said protein present in the first biological sample from said first subject and the amount of said protein present in the second biological sample from said second subject assists in the diagnosis of whether the second subject has liver fibrosis and/or cirrhosis.
2. The method of claim 1 , wherein the amount of at least one protein is determined by Western blot or ELISA.
3. A method of evaluating the expression level of a biomarker for liver fibrosis and/or cirrhosis comprising:
obtaining a first biological sample from a first subject without liver fibrosis and/or cirrhosis, wherein the first subject is a normal subject;
obtaining a second biological sample from a second subject known or suspected of having liver fibrosis and/or cirrhosis; and
determining an amount of at least one protein chosen from SEQ ID NO: 7 and SEQ ID NO: 68 in said first and second biological samples;
wherein a difference of 1.5 fold or more between the amount of said protein present in the first biological sample from said first subject and the amount of said protein present in the second biological sample from said second subject assists in the diagnosis of whether the second subject has liver fibrosis and/or cirrhosis.